相关实验视频

Updated: May 21, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

基于风险分层和病理阶段的异形膜性病症免疫治疗的评估

Yang Yang¹, Yuxin Zhang², Ran Zhang³

¹Department of Nephrology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China; Jiangxi Key Laboratory of Molecular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China.

European journal of pharmacology

|May 19, 2025

概括

与rituximab (RTX) 和cyclophosphamide (CYC) 相比,Tacrolimus和葡萄糖皮质类药物 (GC) 在中度和高风险的异常性膜性病 (IMN) 患者中显著改善了完全缓解 (CR) 率. 此外,TAC+GC还导致了第二阶段IMN的更快的CR.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫抑制疗法免疫抑制疗法
淋巴细胞疾病淋巴细胞疾病

背景情况:

异形膜性病 (IMN) 的治疗策略需要根据风险和病理阶段进行澄清.
目前的治疗选择对于风险分层和病理阶段的IMN患者缺乏明确的指导.

研究的目的:

为了比较tacrolimus (TAC),rituximab (RTX) 和cyclophosphamide (CYC) 在治疗活检证明的IMN的疗效.
根据KDIGO风险分层和病理阶段来评估治疗结果.

主要方法:

成年IMN患者的前性队列研究,其eGFR>50mL/min/1.73m2.
患者按风险 (中等,高,低) 和病理阶段 (II,III) 分类.
治疗组包括TAC + 葡萄皮质类药物 (GC),RTX + GC,CYC + GC,支持性护理 (SC) 和非SC (NSC).

主要成果:

在12个月的中度风险患者中,TAC + GC显示完全缓解 (CR) 率明显高于RTX和CYC + GC.
在高风险患者中,TAC + GC (48.0%) 的CR率最高,其次是CYC + GC (35.6%) 和RTX (16.7%).
在高风险和II期IMN患者中,TAC + GC显示了最短的CR平均时间.

结论:

与RTX和CYC + GC相比,TAC + GC在中度和高风险IMN患者中更有效地实现CR.
TAC + GC疗法提供了一个更快的路线到CR在II阶段IMN.
需要进一步的研究,以根据患者个体特征优化IMN的治疗算法.

关键词:

异常病态的膜性脏病.病理阶段病理阶段缓解缓解是一种缓解.风险分层的风险分层.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.